Ryaltris is currently out of stock due to a voluntary recall initiated by its manufacturer, Teva Pharmaceuticals. The recall is linked to potential degradation of the active pharmaceutical ingredients, olopatadine and mometasone furoate, over time. This degradation could lead to a reduction in the drug's efficacy.
What is Ryaltris and What is it Used For?
Ryaltris is a prescription nasal spray used to treat nasal allergy symptoms in adults and children aged 12 years and older. It combines two active ingredients: olopatadine, an antihistamine, and mometasone furoate, a corticosteroid. Olopatadine works by blocking the action of histamine, a substance the body releases during an allergic reaction. Mometasone furoate reduces inflammation in the nasal passages, which helps relieve symptoms like sneezing, runny nose, itchy nose, and nasal congestion [1].
What is the Specific Reason for the Recall?
Teva Pharmaceuticals issued a voluntary recall of Ryaltris due to a potential for the active ingredients, olopatadine and mometasone furoate, to degrade over time. This degradation might result in a lower concentration of the active ingredients than what is stated on the label, potentially impacting the drug's effectiveness. The recall was initiated after stability studies indicated this possibility [1].
When Did the Recall Happen and What Products Are Affected?
Teva Pharmaceuticals announced the voluntary recall of Ryaltris on March 20, 2024. The recall affects specific lots of Ryaltris nasal spray. Patients and healthcare providers are advised to check the lot numbers of their Ryaltris supply against the list of recalled lots provided by Teva [1].
What Should Patients Do If They Have Recalled Ryaltris?
Patients who have Ryaltris nasal spray from the affected lots should not use it. They should consult with their healthcare provider to discuss alternative treatment options for their allergy symptoms. Patients can return the recalled product to the pharmacy where it was purchased for a refund or dispose of it according to their local guidelines for medication disposal [1].
How Can Patients Get Ryaltris Again?
Until the recalled lots are replaced and the issue is resolved, obtaining Ryaltris may be difficult. Patients should speak with their doctor or pharmacist about when new stock might be available and to explore alternative allergy medications that can provide relief in the meantime. Information on the availability of recalled products is typically updated by the manufacturer and regulatory bodies.
Are There Other Nasal Allergy Sprays Available?
Yes, there are several other nasal allergy sprays available that work similarly to Ryaltris. These include antihistamine-only sprays, corticosteroid-only sprays, and combination sprays. Examples of available medications include fluticasone propionate (Flonase), budesonide (Rhinocort), azelastine (Astelin, Astepro), and ipratropium bromide (Atrovent Nasal) [2]. Your healthcare provider can recommend the most suitable alternative based on your specific allergy symptoms and medical history.
What Are the Risks if a Degraded Product is Used?
Using a Ryaltris nasal spray where the active ingredients have degraded could mean that the medication is less effective at controlling allergy symptoms. While the degradation is not expected to cause immediate harm, it could lead to a worsening of allergic rhinitis symptoms, such as sneezing, runny nose, itchy nose, and congestion, because the medication is not working as intended [1].
How Long Do Drug Recalls Typically Last?
The duration of a drug recall can vary significantly depending on the nature of the issue. For recalls related to manufacturing defects or product degradation, like the Ryaltris situation, the manufacturer must identify and rectify the problem. This often involves revising manufacturing processes, packaging, or stability testing protocols. Once these corrective actions are implemented and verified, the drug can be re-released to the market. The timeline can range from weeks to months, and it is dependent on regulatory approval of the corrective measures.
Sources
1. DrugPatentWatch.com
2. National Institutes of Health. (n.d.). Olopatadine and Mometasone Furoate Nasal